China National Pharmaceutical Group Corporation (CNPGC), commonly referred to as Sinopharm, is a Chinese state-owned enterprise. The corporation was the indirect major shareholder of publicly traded companies Sinopharm Group (sehk: 01099, via a 51–49 joint venture, Sinopharm Industrial Investment, with Fosun Pharmaceutical), China Traditional Chinese Medicine (sehk: 00570, mostly via Sinopharm Group Hongkong Co., Ltd.),[5] Shanghai Shyndec Pharmaceutical (sse: 600420, via a wholly owned research institute based in Shanghai), and Beijing Tiantan Biological Products (sse: 600161, via China National Biotec Group).
China National Pharmaceutical Group was supervised by the State-owned Assets Supervision and Administration Commission of the State Council.[6]
Sinopharm was ranked 109th in the 2021 Fortune Global 500 list.[7]